BriaCell Therapeutics Corp. (BCTX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

BriaCell Therapeutics Corp. (BCTX) closed at USD 3.69 on 2026-10-14, a change of -72.3 % over the past year, with a market capitalization of USD 32.75M.

BriaCell Therapeutics Corp. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

BriaCell Therapeutics Corp. key figures

Previous close

USD 3.69 (2026-10-14)

1-year change

-72.3 %

Market cap

USD 32.75M

Enterprise value

USD 9.3M

P/E ratio (trailing)

-4.09

P/E ratio (forward)

-9.65

EPS (trailing)

-0.92

EPS (forward)

-0.39

PEG ratio

n/a

Price to book

1.13

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

5.03

Employees

n/a

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for BriaCell Therapeutics Corp. and compare it with other stocks.